BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sensus Healthcare Announces Health Canada Approval


11/16/2012 10:36:19 AM

BOCA RATON, Fla., Nov. 16, 2012 /PRNewswire/ -- SensusHealthcare, providers of the SRT-100, the leading alternative for non surgical skin cancer treatment, announces that it has received a Medical Device License from Health Canada, permitting the marketing and sale of its device for treating skin cancer patients. The SRT-100 is a state-of-the-art therapy device for Non Melanoma Skin Cancer. The SRT-100 provides patients with a virtually pain-free non-invasive treatment option, while achieving excellent clinical outcomes that are comparable to surgery, and without scarring. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) and is the leader in the global clinical community. The SRT-100 is proven to be a viable, safe, and cost-effective modality to treat non-melanoma skin cancers in hospitals and private practice settings.

"We are excited to offer this leading technology alternative to the many patients throughout Canada who are diagnosed with skin cancer. We consider Canada as one of the foremost authorities in providing cost effective technologies and we are delighted to have the SRT-100 considered as a viable choice. We are looking forward to working with Canada's healthcare professionals," stated Joe Sardano, President/CEO, Sensus Healthcare.

SRT-100 is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, Health Canada, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.

About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100 systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings.                                                                                                                           

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. 10
michelle@sensushealthcare.com

SOURCE Sensus Healthcare



Read at BioSpace.com

   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES